Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 286

Sort by

Sort Order Select

Journal Articles

Treatment patterns and clinical outcomes in patients with lower-risk Myelodysplastic Syndromes rreated with first-line luspatercept: Findings from a medical record review in France and Germany

Christophe Willekens, Ahmed Hnoosh, Aylin Yucel, Dimana Miteva, Oliver Leismann, Ravi Goyal, Lizzi Esterberg, Maria Jimenez, Ulrich Germing

Blood (2025) 146 (Supplement 1): 6412.

https://doi.org/10.1182/blood-2025-6412

Published: 2025

Journal Articles

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Blood (2025) 146 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2025-2084

Published: 2025

Journal Articles

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

Felicitas Schulz, Udo Holtick, Mareike Verbeek, Edgar Jost, Gesine Bug, Inken Hilgendorf, Nadja Drusenheimer, Christof Scheid, Peter Herhaus, Kathrin Nachtkamp, Paul Jäger, Norbert Gattermann, Sascha Dietrich, Ulrich Germing, Guido Kobbe

Blood (2025) 146 (Supplement 1): 5992.

https://doi.org/10.1182/blood-2025-5992

Published: 2025

Journal Articles

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Blood (2025) 146 (Supplement 1): 791.

https://doi.org/10.1182/blood-2025-791

Published: 2025

Journal Articles

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

Blood (2025) 146 (Supplement 1): 4968.

https://doi.org/10.1182/blood-2025-4968

Published: 2025

Journal Articles

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Blood (2025) 146 (Supplement 1): 3858.

https://doi.org/10.1182/blood-2025-3858

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

Treatment characteristics of 560 unfit patients with AML aged above 65 years: A single center analysis

Felicitas Schulz, Guido Kobbe, Andrea Kündgen, Claudia Lesch, Corinna Strupp, Fabian Czerwensky, Sascha Dietrich, Norbert Gattermann, Ulrich Germing, Paul Jäger

Blood (2025) 146 (Supplement 1): 6961.

https://doi.org/10.1182/blood-2025-6961

Published: 2025

Journal Articles

Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count

Blood (2024) 144 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2024-209450

Published: 2024

Journal Articles

Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML

Katayoon Shirneshan, Hannes Treiber, Katharina Rittscher, Ulrich Germing, Barbara Hildebrandt, Corinna Strupp, Julie Schanz, Ute Windolph, Christina Ganster, Detlef Haase

Blood (2024) 144 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2024-194186

Published: 2024

Journal Articles

Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Maria Diez-Campelo, Elizabeth Esterberg, Ravi K. Goyal, Mrudula B. Glassberg, Aylin Yucel, Julien Rombi, Keith L. Davis, Maria Jimenez, Dimana Miteva, Ahmed Hnoosh, Ulrich Germing

Blood (2024) 144 (Supplement 1): 5055.

https://doi.org/10.1182/blood-2024-206948

Published: 2024

Journal Articles

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Blood (2024) 144 (Supplement 1): 666.

https://doi.org/10.1182/blood-2024-194405

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Treatment with 5-Azacytidine in High Risk MDS, CMML and AML: A Single Center Analysis with Regard to Days in Hospital and Days in Outpatient Clinic

Corinna Strupp, Annika Kasprzak, Andrea Kündgen, Fabian Czerwensky, Sascha Dietrich, Ulrich Germing

Blood (2024) 144 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2024-205650

Published: 2024

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Luca Lanino, Saverio D'Amico, Giulia Maggioni, Najla H. Al Ali, Yu-Hung Wang, Carmelo Gurnari, Nico Gagelmann, Jan Philipp Bewersdorf, Somedeb Ball, Paola Guglielmelli, Manja Meggendorfer, Anthony M. Hunter, Anne Sophie Kubasch, Erica Travaglino, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Cristina Astrid Tentori, Alessandro Buizza, Elisabetta Sauta, Matteo Zampini, Elena Riva, Gianluca Asti, Mattia Delleani, Francesca Ficara, Armando Santoro, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Tariq Kewan, Ilaria Carola Casetti, Hussein Awada, Blanca Xicoy, Vladan Vucinic, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Angela Consagra, David Sallman, Wolfgang Kern, Massimo Bernardi, Patrizia Chiusolo, Lorenza Maria Borin, Maria Teresa Voso, Lisa Pleyer, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Guillermo Garcia-Manero, Sanam Loghavi, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Nicolaus Kröger, Pierre Fenaux, Michaela Fontenay, Valeria Santini, Torsten Haferlach, Ulrich Germing, Eric Padron, Marie Robin, Francesco Passamonti, Eric Solary, Alessandro M. Vannucchi, Gastone Castellani, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2024-204826

Published: 2024

Journal Articles

Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Blood (2024) 144 (Supplement 1): 1341.

https://doi.org/10.1182/blood-2024-210352

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment patterns and clinical outcomes in patients with lower-risk Myelodysplastic Syndromes rreated with first-line luspatercept: Findings from a medical record review in France and Germany

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Treatment characteristics of 560 unfit patients with AML aged above 65 years: A single center analysis

Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count

Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML

Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Treatment with 5-Azacytidine in High Risk MDS, CMML and AML: A Single Center Analysis with Regard to Days in Hospital and Days in Outpatient Clinic

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only